文献速递淋巴瘤

特发性多中心型Castleman病(iMCD)-特发性浆细胞性淋巴结病:一种具有不同临床特征和更优生存的iMCD-非特指型独特亚型

Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
PubMed 文献 · Br J Haematol · 2024-02-15

该回顾性分析纳入228例iMCD-NOS患者,其中103例(45.2%)为iMCD-IPL。iMCD-IPL患者炎症状态显著更高但总生存更长;按CDCN严重度分类,iMCD-IPL组内严重与非严重患者总生存无显著差异。相比类淋巴瘤治疗,类多发性骨髓瘤和IL-6阻断治疗在iMCD-IPL组中应答率显著更高、至下次治疗时间更长。

要点

  • 228例iMCD-NOS中103例(45.2%)为iMCD-IPL。
  • iMCD-IPL炎症状态显著更高但总生存更长。
  • iMCD-IPL组内按CDCN严重度分类,严重与非严重患者总生存无显著差异。

核心结论

  • iMCD-IPL具有独特性,作者认为应将其视为iMCD-NOS的一个新亚型。

研究设计与样本

  • 回顾性分析228例iMCD-NOS患者,其中103例(45.2%)为iMCD-IPL,比较iMCD-IPL与无IPL的iMCD-NOS患者的临床特征和结局。

主要发现

  • iMCD-IPL患者炎症状态显著更高但总生存更长。
  • 按CDCN严重度分类,iMCD-IPL组内严重与非严重患者总生存无显著差异。
  • 相比类淋巴瘤治疗,iMCD-IPL组中类多发性骨髓瘤和IL-6阻断治疗应答率显著更高、至下次治疗时间更长。

关键数值与推荐

  • iMCD按CDCN共识标准分为iMCD-TAFRO和iMCD-NOS。
  • iMCD-IPL以多克隆高丙种球蛋白血症、浆细胞型/混合型淋巴结组织病理学和血小板增多为特征。

临床怎么用

  • 作者认为iMCD-IPL应被视为iMCD-NOS的一个新亚型。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Idiopathic multicentric Castleman disease (iMCD) is subclassified into iMCD-thrombocytopenia, anasarca, reticulin fibrosis, renal dysfunction, organomegaly (TAFRO) and iMCD-not otherwise specified (NOS) according to the Castleman Disease Collaborative Network (CDCN) consensus criteria. With a deeper understanding of iMCD, a group of patients with iMCD-NOS characterised by polyclonal hypergammaglobulinaemia, plasmacytic/mixed-type lymph node histopathology and thrombocytosis has attracted attention. This group of patients has been previously described as having idiopathic plasmacytic lymphadenopathy (IPL). Whether these patients should be excluded from the current classification system lacks sufficient evidence. This retrospective analysis of 228 patients with iMCD-NOS identified 103 (45.2%) patients with iMCD-IPL. The clinical features and outcomes of patients with iMCD-IPL and iMCD-NOS without IPL were compared. Patients with iMCD-IPL showed a significantly higher inflammatory state but longer overall survival. No significant difference in overall survival was observed between severe and non-severe patients in the iMCD-IPL group according to the CDCN severity classification. Compared with lymphoma-like treatments, multiple myeloma-like and IL-6-blocking treatment approaches in the iMCD-IPL group resulted in significantly higher response rates and longer time to the next treatment. These findings highlight the particularities of iMCD-IPL and suggest that it should be considered a new subtype of iMCD-NOS.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Gao YH, Liu YT, Zhang MY, et al. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. Br J Haematol. 2024. PMID: 38356434. doi:10.1111/bjh.19334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。